GRAIL is a healthcare company specializing in early cancer detection by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to developed a multi-cancer early detection blood test.
Estimated valuation today
-91.36% since last round
Calculated based on estimated multiplier and revenue.
Estimated multiplier for Grail
Calculated based on public comps and hype multiple.
Update this based on your knowledge or projections. Calculations use last 12 months revenue.
Currently selected comps have a median growth rate of 11.40%
This premium represents how much of a bonus the company receives on its valuation for its additional growth compared to the selected public comps. The valuation is multipled by the Hype Multiple to get the final valuation. You can read more about this from a16z.
The last round was 2 years ago.
We estimate company valuation by comparing it to similiar companies in the public market. The revenue multipler is calculated by taking a company's current valuation and dividing it by its total revenue.
Multiple at last round
Industry – Healthcare
Last updated 5 mins ago.
With a revenue of $150M and a Hype Multiple of 1.5x,
Grail is estimated to be worth $368M.